UroPredict relies on real-world data from the UroCCR network to generate algorithms and implement them nationally for clinical research purposes.
A collaboration between the UroCCR Network, the Cancer Committee of the French Association of Urology, and SOPHiA GENETICS has enabled the development and validation of artificial intelligence algorithms based on the UroCCR database. The first predictive models produced enable quantification of the risk of upstaging of a kidney tumour classified as cT1-2 on preoperative imaging and pT3 on pathological analysis, as well as the risk of recurrence after surgery for localised or locally advanced kidney cancer.
UroPredict won the French government’s “Data, IA & Parcours de santé” Call for Expression of Interest led by the Strategic Committee of the Healthcare Industries and Technologies Sector for the Government.
Estimation of the recurrence risk after a non-metastatic kidney cancer surgery
